The leading scientist of his clinical trials Chinese vaccine Sinovac in Indonesia died today, Wednesday, and her death is said to be due to coronavirus, as reported by local media.
Her death Novilia Szafri Bakhtiar takes place at a time when the numbers of new deaths due to Covid-19 are reaching record levels in Indonesia, one of the countries where Sinovac is widely administered.
The Kumparan news agency reported that Novilia had died of a coronavirus. Sindonews, for its part, citing an official of the state pharmaceutical company BioFarma, reported that the scientist buried according to Covid-19 protocols.
The Minister of State Enterprises Eric Thohir In a post on Instagram, he mourned the “huge gap” that Nonilia leaves in BioFarma, which prepares the vaccine, according to APE BPE. She did not say what caused her death.
“He was a leading scientist and led dozens of clinical trials conducted by BioFarma, including clinical trials of the vaccine against Covid-19 in cooperation with Sinovac “, he said.
“It simply came to our notice then tens of millions people in Indonesia as part of our effort to get rid of the Covid-19 pandemic. “
BioFarma did not immediately respond to a request for comment comment about the death of Novilia, who was just over 50 years old.
Concern over the efficacy of the Sinovac vaccine
It is pointed out that infections and deaths sanitary in Indonesia – who have received the Sinovac vaccine – have added questions about its effectiveness in preventing hospitalization and death.
According to the independent data set COVID-19 report, 131 health workers, mostly vaccinated with the Sinovac vaccine, have died since June, including 50 in July.
Indonesia also reported today that it recorded for the first time more than 1,000 daily deaths because of Covid-19 within 24 hours and confirmed 34.379 infections.
The last wave of infections is fed by Delta mutation, first found in India.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
